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Abstract 
 
 
 
A study towards the synthesis of a new fulvestrant analogue with improved 
bioavailability was carried out. In this work a twelve-step synthetic route starting from β-
estradiol was optimized and a palladium (Pd)-catalyzed endo-selective Heck reaction for 
the functionalization of an advanced intermediate was investigated. 
 
 
 
Abbreviations 
iv 
Abbreviations 
Ac Acetyl 
Ar Aryl 
Bu Butyl 
calcd Calculated 
cat Catalyzed 
CI  Chemical ionization 
DCM  Dichloromethane 
DDQ 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEPT Distortionless enhancement of polarisation transfer 
DIBAL-H Diisobutylaluminum hydride 
DMAP 4-Dimethylaminopyridine 
DMF  Dimethylformamide 
EI Electron impact 
eq. Equivalent 
ER Estrogen receptor 
ESI Electrospray ionization 
Et Ethyl 
FT Fourier Transform 
i Iso 
IR Infrared 
L Ligand 
Me Methyl 
MOM  Methoxymethyl 
mp Melting point 
MS  Mass spectroscopy 
NBS N-Bromosuccinimide 
NMR  Nuclear magnetic resonance 
PG Protecting group 
Ph Phenyl 
PMA Phosphomolybdic acid 
Pr Propyl 
R Organic substituent (if not otherwise specified) 
rt Room temperature 
sat Saturated 
SM Starting material 
TBS Butyldimethylsilyl 
TCCA Trichloroisocyanuric acid 
Tf Triflate (trifluoromethanesulfonate) 
THF Tetrahydrofuran 
TMS Trimethylsilyl 
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1. Introduction 
 
1.1 Steroids
1
 
Steroids are polycyclic organic compounds which contain a basic carbon framework 
consisting of four fused rings, where three cyclohexane rings (named rings A, B and C) 
form the skeleton of a perhydro-derivative of phenanthrene, while the D-ring has a 
cyclopentane structure. Hundreds of different steroids are found in Nature, where the 
archetype just described may contain unsaturations, an alkyl chain on C-17, an aromatic 
A-ring, hydroxyl groups, methyl groups or other functionalities; all of them are described 
using a specific numbering as shown in (Fig. 1). 
 
Fig. 1. Steroid skeleton and numbering 
 
Each ring junction could be cis or trans, but it turns out that all steroids have all trans 
junctions except where rings A and B join which is sometimes cis. Examples are 5α-
gonane (all trans) and 5β-gonane (rings A and B fused cis), the simplest existing steroids. 
(Fig. 2). Because of their structure, steroids cannot undergo a ring flip, so even the 
isomers of the simplest examples cannot interconvert.  
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Fig. 2. Spatial arrangement of the steroidal core 
 
1.1.1 Estrogens
2
 
Estrogens are a group of steroid hormones that are important for sexual and 
reproductive development mainly in women. They are also referred to as female sex 
hormones. The term "estrogen" refers to all of the chemically similar hormones in this 
group, which include β-estradiol, estriol and estrone. (Fig. 3). 
 
 
Fig. 3. Estrogens 
 
1.2 Fulvestrant in Breast Cancer Treatment 
Breast cancer represents 25% of all cases of cancer in women, making it the leading form 
and resulting in more than 1.6 million cases annually and causing 522,000 deaths in 2012 
in the USA
3,4
. Despite these numbers, breast cancer mortality has continuously decreased 
since the late 1970s in developed countries thanks to early detection and research for new 
drugs and treatments
5
. 
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In this scenario hormone therapies represent an important treatment for hormone-
receptor-positive breast cancer
6,7
, i.e. a cancer formed by cells that receive signals from 
certain types of hormone that could promote their growth. If the carcinoma has receptors 
for estrogen is called estrogen-receptor-positive (or ER+), while it is called progesterone-
receptor-positive (PR+) if it has progesterone receptors
8
. Roughly two out of every three 
breast cancer phenotypes test positive for hormone receptors, and this ratio becomes 
higher in older women than in younger women
9
.  
These findings have led to the development of molecules able to block estrogen-mediated 
cell signalling
10
, ability called “antagonist effect”, in order to fight ER+ breast 
carcinomas. For the last three decades, the most widely used drug as a hormonal therapy 
has been tamoxifen (Novaldex®), which indeed acts as an antagonist in the breast tissues 
and effectively treats patients, but it also acts as an agonist in other tissues
11,12
.  
This means that tamoxifen and its class of drugs could lead, as a side effect, to the 
development of resistance towards the primary treatment and to an increased risk of 
carcinomas in other parts of the body
11
. These drawbacks drove the research through the 
development of new drug molecules free of these undesired effects. (Fig. 4) 
 
Fig. 4. Examples of drugs used in hormonal therapy 
 
Fulvestrant (‘Faslodex®’), developed in 1987, is the first in a class of a new type of 
hormonal therapy: it acts as a ‘pure’ estrogen antagonist and therefore possesses no 
agonist effect
13
. Tamoxifen remains widely used against breast cancer, but fulvestrant has 
been proved to have other interesting properties in addition to its “pure antagonism”. 
Faslodex® is indeed quite active in the treatment of patients with ER+ breast carcinoma 
who didn’t respond positively to other endocrine therapies, and also good results have 
been obtained using it in combination with other agents in order to increase its 
efficacy
14,15,16
. 
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The main problem with fulvestrant is its low oral bioavailability, so it has to be injected 
intramuscularly. This implicates more pain for the patient as well as a higher risk of 
inflammation at the site of administration. For these reasons, research focused on the 
development of orally active pure estrogen-receptor antagonists, and efforts have been 
made to modify the alkyl side chain of fulvestrant. This led to the synthesis and 
biological assessment of compounds such as CH4893237
17
 and ZK-703
18
, for which 
research is still in progress
19
 (Fig. 5). 
 
Fig. 5. Fulvestrant analogues with increased bioavailability 
 
1.3 Previous Work 
The issue of oral bioavailability has previously been faced in our laboratory on a 
different medicinal chemistry project. Our collaborators were interested in developing a 
selective cyclin-dependent kinase inhibitor
20
. A first analogue, BS-181, showed 
interesting inhibitory activity against a range of different kinases (Fig. 6), but the real 
achievement it turned out to be the substitution of the aminoalkyl fragment with a 
trihydroxy side chain, affording compound BS-194. This modification led to an 
important increase in the oral bioavailability without significant changes in the desired 
biological functions of the drug
21
. 
 
Fig. 6. Increase of the bioavailability of BS-181  
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These findings were therefore used in the design of a new analogue of fulvestrant, on 
which the same trihydroxyamino side chain was substituted onto the steroidal core of 
fulvestrant (compound 237, Fig. 7). Instead of modifying the C-7 alkyl side chain, it was 
seen as a good idea to attach the bioavailability enhancing triol fragment via an ethylene 
linker on C-11 or on C-9 of the steroidal core.  
Examples of modification of the C-11/C-9 position of estrogen derivatives have already 
been reported in the literature
22
, but nothing concerning a similar compound carrying 
also the side chain on C-7 and C-11 functionalized with side chains. For this reason and 
for the advantages that it could offer, the synthesis of fulvestrant analogue 237 represents 
a very challenging synthetic goal. 
 
Fig. 7. Synthetic targets as new fulverstrant analogues 
 
The synthesis of fulvestrant analogue 237 has been previously attempted in the Barrett 
group
23
. In the first attempt an allyl group was put in the C-11 position. Compounds 238a 
and 238b were obtained after a five-step sequence. In the next step efforts were made to 
oxidize the C-6 position, in order to introduce the alkyl side chain on the C-7 position. 
Unluckily, alcohol 239 was not obtained (Scheme 8) 
 
 
Scheme 8. First attempt in the synthesis of fulvestrant analogue 237 
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A second alternative approach for the synthesis of target molecule 237 was to install the 
alkyl side chain in an early stage
23
 (Scheme 9). To do so, intermediates 240a and 240b 
were synthetizes in three steps, but the alkylation reaction to obtain compound 242 was 
unsuccessful. 
 
 
Scheme 9. Second attempt in the synthesis of fulvestrant analogue 237 
 
The third attempt
24
 that has been undertaken to reach synthetic target 237 was to attach 
the side chain on C-7 by way of a copper mediated 1,6-addition of the alkyl bromide 
below to dienone 6. C-9 and C-11 positions have then to be oxidized connecting them 
with a double bond with DDQ. Dienone 6 was successfully synthetized in 5 steps, and 
also the conjugate addition was successful, giving compound 248a (Scheme 10). 
 
 
Scheme 10. Installation of the southern chain 
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The TBS protecting group in ketone 248a was then hydrolyzed and acetylated in the 
same step to give alkylated enone 265, that was subsequently successfully aromatized to 
phenolic steroid 266 (Scheme 11).  
 
Scheme 11. Replacement of –OTBS group with acetate and aromatization 
 
The next step was an oxidation carried out with DDQ, which afforded no desired product 
in any condition tested (Scheme 12). 
 
Scheme 12. DDQ oxidation 
 
The fourth attempt
24
 to synthetize fulvestrant analogue 237 was to introduce a 
functionalized carbon on the C-7 position and then use it to lead the way to the 
functionalization of C-9. Starting from β-estradiol, compound 6 was synthetized in 5 
steps, then a carbon was added on C-7 position through a 1,6-conjugate addition of 
cyanide giving compound 7. Alcohol 11 was synthetized in 4 more steps, but the real 
achievement was the success in the synthesis of ether 12. 
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Scheme 13. Fourth try in the synthesis of fulvestrant analogue 237 
 
At this point an allylation was attempted in order to functionalize ether 12 on the C-9 
position with an allyl group. Unexpectedly, an elimination occurred instead, leading to 
alkene 13 (Scheme 14). 
 
 
Scheme 14. Elimination reaction towards alkene 13 
 
The synthesis of alkene 13 was a success in any case, but its potential role in the 
synthesis of fulvestrant analogues 237 wasn’t further investigated. 
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2. Project Goals 
 
This project is part of a study undertaken to increase fulvestrant bioavailability. The main 
goal is the synthesis of a novel intermediate as a step forward into the synthesis of 
fulvestrant analogues 237 (Fig. 7). 
 
Fig. 7. Fulvestrant analogues 237 
 
In previous work in Barrett research group
24,25
, synthesis of alkenol 13 was achieved in 
twelve steps from commercially available β-estradiol (Scheme 15). 
 
Scheme 15.  Retrosynthesis towards alkenol 13 from β-estradiol 
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After synthetizing an appreciable amount of alkenol 13, the purpose of this project was to 
synthetize silyl chloride 18 in three steps and use it to functionalize alkenol 13 to give 
silyl steroid 14 (scheme 16), a novel advanced intermediate
26
. 
 
Scheme 16. Idea for the synthesis of a novel advanced intermediate 14 
 
If the silylation of alkenol 13 is successful, an intramolecular modified Heck coupling
26
 
will be tried in order to get a bicyclic steroid such as 19 and/or 20 (Scheme 17). 
 
Scheme 17. Hypothesized products of the Heck Coupling 
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3. Results and Discussion 
3.1 Synthesis of 19-nortestosterone (3) 
For economic reasons, it was decided to synthetize commercially available 19-
nortestosterone (3) from the much more cheaper and commercially available β-estradiol 
in three steps, following literature procedures
27,28
 (Scheme 18). 
Firstly, the methylation of the aromatic hydroxyl of β-estradiol was carried out. Methyl 
iodide and potassium carbonate were refluxed with the substrate in acetonitrile giving 
methyl ether 1 in 95% yield. The second step was the Birch reduction of aromatic 
compound 1 in order to obtain unconjugated diene 2: sodium dissolved in liquid 
ammonia and THF in presence of isopropanol at -50°C gave desired product 2 in > 90% 
yield. Finally, enol ether 2 was hydrolyzed in aqueous acidic conditions to 19-
nortestosterone 3 in 95% yield. 
 
 
 
Scheme 18. Synthesis of 19-nortestosterone 3 
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This hydrolysis passes through an intermediate β,γ-unsaturated ketone 2’, which 
isomerizes straight away to give the α,β-unsaturated ketone 3 as a result of the keto enol 
tautomerism. 
 
3.2 Functionalization of the C-7 Position 
In the first step enone 3 was dissolved in acetic anhydride and treated with sodium iodide 
and trimethylsilyl chloride to give diacetate 5 in a single high-yielding step
29
. Treatment 
of 5 with NBS in presence of water, followed by heating and addition of base
30
 led to the 
formation of α,β,γ,δ-unsaturated ketone 6 in 85% yield (Scheme 19). 
 
 Scheme 19. Synthesis of dienone 6 
 
Dienone 6 underwent a hydrocyanation
31
 to give nitrile 7 in 76% yield (Scheme 3). For 
this 1,6-conjugated addition of cyanide, one molar diethylaluminum cyanide solution in 
toluene was used as soluble and bulky source of CN
-
, in order to achieve high 
diastereoselectivity in the product. The cyclic enone moiety in ketone 7 was then 
aromatized with cupric bromide and lithium bromide in refluxing acetonitrile
31
, giving 
nitrile 8 in 89% yield (Scheme 20). 
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Scheme 20. Synthesis of nitrile 8 from dienone 6 
 
3.3 Functionalization of the C-9 and C-11 Positions 
3.3.1 Reduction of Nitrile 8 with DIBAL-H 
In previous works in the Barrett Group
24
 and in the literature
31
 the reduction of nitrile 8 
to aldehyde 9 was carried out with 1.67 equivalents of DIBAL-H at room temperature. In 
our hands, attempted reproduction of these conditions gave aldehyde 9 in a yield that did 
not exceed 40%. Considering the reactivity of DIBAL-H and the presence of additional 
functionality in the substrate (i.e. an ester, a phenolic hydroxyl and a nitrile in the 
molecule), the number of equivalents of hydride was increased to 4.2: one equivalent 
would deprotonate the hydroxyl, two equivalents would reduce the ester to an alcohol 
and the fourth equivalent would actually reduce the aliphatic cyanide to an imine salt 8’. 
This would hydrolyze to the corresponding aldehyde after aqueous work-up (Scheme 
22). These modified reaction conditions proved effective and nitrile 8 was reduced to 
aldehyde 9 in 81% yield (Scheme 21). 
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Scheme 21. Reduction of nitrile 8 to aldehyde 9 
 
 
Scheme 22. Proposed mechanism for DIBAL-H reduction of 8 (deprotonation of phenolic hydroxyl, 
reduction of the ester and reduction of the nitrile are displayed in this order for explanatory reasons). 
 
3.3.2 Reduction of Aldehyde 9 to Alcohol 11 
First the two hydroxyl groups of aldehyde 9 were protected as diacetate 10 using acetic 
anhydride catalyzed by DMAP and a tertiary amine
31
. In the next step the aldehyde was 
reduced using sodium borohydride in ethanol at 0 °C
31
 giving alcohol 11 (Scheme 23). 
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Scheme 23. Protection and reduction of alcohol 9 to aldehyde 11 
 
During the course of this reaction alcohol 10’ was detected and isolated, as the basic 
conditions led to partial cleavage of the aromatic acetate. In an attempt to avoid this, the 
same reaction was performed in presence of a buffer salt (NaH2PO4), however no 
improvement was observed. On the other hand it was found that simply neutralizing the 
reaction mixture with a reverse quench into a saturated solution of ammonium chloride, 
the cleavage of the aromatic ester was reduced and alcohol 11 was obtained with a 
reproducible yield of 80%. 
 
3.3.3 Synthesis of Alkenol 13 
Following the conditions previously reported by the Barrett research group
24
, alcohol 11 
was oxidized to the benzylic ether 12 necessary for subsequent conversion to alkenol 13. 
Thus alcohol 11 was refluxed with a mixture of lead (IV) acetate and iodine in carbon 
disulfide to give bicyclic ether 12 in 81% yield. After, substrate 12 was converted to 
alkenol 13 via an elimination reaction with iron (III) chloride and allyltrimethylsilane in 
dichloromethane
25
 in 76% yield (Scheme 24). 
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Scheme 24. Synthesis of alkanol 13 from alcohol 11 
 
3.4 Attempts Towards the Synthesis of the Silyloxycycle 
Steroid Derivative 
With substrate 13 in hand, it was decided to investigate an intramolecular Heck reaction 
of this steroid derivative. According to the literature
26
 an endo-selective palladium-
catalyzed Heck reaction of iodomethylsilyl ethers of aliphatic alkenols has been 
developed to obtain silyloxycycles (Scheme 25).  
 
Scheme 25. Preparation of a Silyloxycycle using a Heck Coupling  
 
3.4.1 Synthesis of Silylating Agent 18 
Chloro(iodomethyl)diisopropylsilane 18 was synthetized from commercially available 
(chloro)diisopropylsilane 15 in three steps
26
. First substrate 15 was converted into silane 
16 by reaction with chloroiodomethane and a complex of methyllithium and lithium 
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bromide in THF at -78 °C. Displacement of the chloride in compound 16 with iodide 
through a Finkelstein reaction gave (iodomethyl)diisopropylsilane 17. In the last step 
substrate 17 was oxidized with trichloroisocyanuric acid (TCCA) in DCM at 0 °C to give 
chloro(iodomethyl)diisopropylsilane 18 with an overall crude yield of 79% (Scheme 26). 
 
Scheme 26. Synthesis of silylating agent 18 
 
3.4.2 Silylation of Alkenol 13 
Alkenol 13 was successfully silylated by reacting with silylating agent 18 in a DMAP 
catalyzed reaction with triethylamine in DCM at 0°C
26
 giving iodomethylsilyl ether 14 in 
89% yield (Scheme 27), a novel intermediate. 
 
Scheme 27. Silylation of alkenol 13 with silylating agent 18 
 
The silylation catalytic cycle that took place is shown in (Scheme 28). The silyl chloride 
is activated by DMAP, while the stoichiometric triethylamine neutralizes the HCl 
formally eliminated during the reaction. 
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Scheme 28. Silylation catalytic cycle with DMAP 
 
3.4.3 The Silyl Methyl Heck Coupling 
The silyl methyl Heck coupling is proposed to proceed via a hybrid-Pd-radical catalytic 
cycle
26
 shown in (Scheme 29).  
 
Scheme 29. Catalytic cycle for the silyl methyl Heck reaction 
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1. Oxidative addition of the substrate to the catalyst, followed by homolysis 
produces radical A and the Pd(I) species, avoiding a premature β-hydride 
elimination. 
2. Cyclization of radical A can lead to cyclic radical B. 
3. Recombination of radical B with Pd(I) species produces alkylpalladium species 
C. 
4. β-hydride elimination of C, which can be induced with silver salts, gives product 
D and Pd(II) species. 
5. Reductive elimination of HI, in the presence of a base, regenerate the catalytic 
species Pd(0). 
 
Although 6-9 membered silyloxycycle with endo double bond are the most common 
products, silyloxycycles with exo double bond are almost always isolated as minor 
products and at times obtained as major products.  
 
3.4.4 Possible products of the silyl methyl Heck reaction on substrate 14 
If the reaction were to work on substrate 14,  three products can be hypothesized, such as 
19, 20 and 22 (Scheme 30). Product 22 is very unlikely to form as its structure would be 
forbidden by the Bredt’s rule. 
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Scheme 30. Possible products of the silyl methyl Heck reaction on substrate 14. The silicon atoms 
shown in the scheme are tetravalent, but two –iPr substituents were omitted for drawing reasons. 
 
3.4.5 Pd-catalyzed silyl methyl Heck reaction applied on substrate 14 
After some consideration about possible products, the reaction was attempted on 
substrate 14 by treatment with palladium (II) acetate, silver triflate, 
diisopropylethylamine, 1-diphenylphosphino-1′-(di-tert-butylphosphino)ferrocene as 
ligand and toluene as solvent (scheme 31). The reaction was run in a sealed tube, under 
argon atmosphere in a glove box, and different conditions were screened (Tab 1). In each 
case the reaction was monitored by TLC analysis and was stirred up to 72 hours. 
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Scheme 31. Silyl methyl Heck reaction on substrate 14 
 
Entry Temperature Pd(OAc)2 Ligand Results 
1 110 °C 0.1 eq. 0.2 eq. decomposition 
2 135 °C 0.1 eq. 0.2 eq. decomposition 
3 135 °C 0.5 eq. 1.0 eq. products not characterized 
 
Tab 1. Screening 
 
In one run (entry 3) two clear spot were detected by thin layer chromatography analysis. 
The reaction mixture was filtered through celite and a purification by flash column 
chromatography in DCM was attempted. Unfortunately, given the scale of the reaction 
and the instability of the product mixture, it was not possible to characterize any product 
in the isolated fractions. 
It is possible that the reaction was unsuccessful because the 7 or 8 membered ring which 
would form would be too strained. This is because 4 of its atom would belong to the 
steroidal core and therefore are roughly on the same plane (Fig. 8) 
 
 
Fig. 8. Proposed 3D drawing of target molecule 20 
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3.5 Future work 
The Pd-catalyzed silyl methyl Heck reaction will be further investigated: 
1. Conditions 3 will be run with a greater amount of substrate 14 to try to 
characterize the product. 
2. The reaction will be run again without silver triflate. It is known that silver salts 
promote the β-elimination stage during the catalytic cycle, but in this case silver 
cation could induce a premature β-elimination between the oxidative addition and 
the homolysis, and such a thing would compromise the formation of radical A 
(Scheme 29). 
3. In case the reaction was not successful due to steric hindrance, a less bulky 
silicon fragment can be synthetized and attached to alkenol 13, i.e. with methyl 
groups instead of isopropyl ones. That would lead to a less hindered 
iodomethylsilyl ether such as compound 24 (Scheme 32). 
 
Scheme 32. Proposed option with a less bulky silicon moiety 
 
4. If the reaction did not work because the ring that would form would be too 
strained, a reasonable option would be to increase the number of carbon atoms 
between the iodine and the double bond (compound 26) using a different 
silylating agent (25), in order to form a less strained ring (Scheme 33). 
 
Scheme 33. Proposed option with a silicon   
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In case the Heck coupling will not give any positive result, alkenol 13 remains a valuable 
advanced intermediate. Many options can be evaluated in order to functionalize the 
double bond and attach a substituent on C-9 or C-11 (Fig. 9) 
 
Fig. 9. Advanced intermediate 13
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4. Experimental 
4.1 General Procedures 
All reagents and solvents were supplied from commercial sources, and used as supplied 
unless otherwise indicated. Reactions requiring anhydrous conditions were conducted in 
oven-dried glassware under an inert atmosphere (nitrogen or argon), and using anhydrous 
solvents. DCM, Et3N, and pyridine were distilled over CaH2. THF was distilled over 
Na/benzophenone. MeOH was distilled over Mg(OMe)2. Anhydrous chemicals were 
obtained commercially. 
All reactions were monitored by thin-layer chromatography (TLC) using Merck silica gel 
60 F254 plates (0.25mm). TLC plates were visualized using UV light (254nm) and/or by 
staining in vanillin or PMA, as appropriate.  
Flash column chromatography was performed using silica gel (Sigma-Aldrich) 40-63 μm 
60 Å with a solvent system that will be described in the relevant procedure. 
Infrared spectra were recorded neat on a Perkin Elmer Frontier FT-IR Spectrometer. 
Reported absorptions are strong or medium strength unless stated otherwise and given in 
wavenumbers (cm
-1
). 
1
H and 
13
C NMR were recorded on a Bruker Avance 400 spectrophotometer at 400 MHz 
and 100 MHz respectively and on a Bruker Avance 500 at 500 MHz and 125 MHz 
respectively. Chemical shifts (δ) are quoted in ppm (parts per million) downfield from 
tetramethylsilane, referenced to residual solvent signals: 
1
H δ = 7.26 (CHCl3); 
13
C δ = 
77.16 (CDCl3). Carbon multiplicities were determined by DEPT experiments. The signal 
multiplicity is quoted as follow: coupling constant (J), singlet (s), doublet (d), triplet (t), 
quadruplet (q), quintuplet (quin), sextet (sext), septet (sep) broad (br), apparent (app), 
multiplet (m), double-doublet (dd), double-double-doublet (ddd).  
Low and high resolution mass spectra (ESI, CI) were recorded by the Imperial College 
London Department of Chemistry Mass Spectroscopy Service using a Micromass 
Autospec Premier and Micromass LCT Premier spectrometer. 
Melting points were determined using a Leica VMTG heated-stage microscope and are 
uncorrected. 
Specific rotations [α]
D
 were recorded on a Perkin-Elmer 214 polarimeter at 589 nm  
Experimental 
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(Na D-line) with a path length of 0.5 dm. Concentrations (c) are quoted in g/100 mL and 
specific rotations are quoted in units of deg●dm-1cm3g-1 at the indicated temperature (in 
°C).  
 
4.2 Synthesis 
(8R,9S,13S,14S,17S)-3-methoxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-
cyclopenta[α]phenanthren-17-ol (1) 
 
To a solution of β-estradiol (5.0 g, 18.36 mmol, 1.0 eq.) in acetonitrile (200 mL) was 
added potassium carbonate (12.69 g, 91.8 mmol, 5.0 eq.) and methyl iodide (15.64 g, 
110.2 mmol, 6.0 eq.). This mixture was refluxed for 16 h, then cooled at room 
temperature and the solvent was evaporated in vacuo. The solid residue was suspended in 
water (200 mL) and the aqueous layer extracted with DCM (3 x 50 mL). The combined 
organic extracts were dried over MgSO4 and the solvent removed in vacuo giving crude 
compound 1 >90% pure by NMR. Purification by flash column chromatography (pentane 
: ethyl acetate, 80 : 20) afforded methyl ether 1 (4.99 g, 95% yield) as a white solid. 
Rf 0.58 (pentane : ethyl acetate, 70 : 30); mp 80–82 °C; [α]D
28
 +10 (c 1.00, CHCl3); IR 
(thin film) 3460 (br), 2932, 2847, 1613, 1506, 1252 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
7.21 (d, 1H, J = 8.5 Hz, Ar-H), 6.71 (dd, 1H, J = 8.5, 2.8 Hz, Ar-H), 6.63 (d, 1H, J = 2.8 
Hz, Ar-H), 3.78 (s, 3H, Ar-OCH3), 3.76–3.69 (m, 1H, CHOH), 2.93–2.78 (m, 2H), 2.37–
2.26 (m, 1H), 2.25–2.06 (m, 2H), 1.99–1.91 (m, 1H), 1.91–1.84 (m, 1H), 1.75–1.65 (m, 
1H), 1.57–1.13 (m, 8H), 0.78 (s, 3H, CCH3); 
13
C NMR (100 MHz, CDCl3) δ 157.4, 38.0, 
132.6, 126.3, 113.8, 111.5, 81.9, 55.2, 50.0, 43.9, 43.3, 38.8, 36.7, 30.6, 29.8, 27.2, 26.3, 
23.1, 11.0; HRMS (ES+) m/z: [M+H]
+
 calcd for C19H27O2 287.2011, found 287.2023. 
The analytical data are consistent with the data reported in the literature. 
 
Experimental 
26 
(8R,9S,13S,14S,17S)-3-methoxy-13-methyl-4,6,7,8,9,11,12,13,14,15,16,17-
dodecahydro-1H-cyclopenta[α]phenanthren-17-ol (2) 
 
A solution of protected phenol 1 (12.2 g, 42.6 mmol, 1.0 eq.) in isopropanol (40 mL) and 
THF (80 mL) was added to liquid ammonia (500 mL) at –78 °C. The resulting white 
viscous suspension was stirred vigorously for 10 min. with an oversized stir bar, then 
sodium (10.78 g, 468.6 mmol, 11.0 eq.) was added in small pieces over 10 min giving the 
mixture a deep blue colour. The reaction mixture was allowed to warm up between -55 
and -45 °C and after 1.30 h the reduction is completed. Methanol (80 mL) was added 
slowly to quench the reaction, and the mixture was allowed to reach room temperature in 
an open flask. The residue was suspended in water (300 mL) and the aqueous layer 
extracted with DCM (3 x 50 mL). The combined organic extracts were dried over 
MgSO4 and the solvent removed in vacuo giving cyclohexadiene 2 as a white solid, more 
than 95% pure by NMR (12.16 g, >90% yield). 
Rf 0.42 (pentane : ethyl acetate, 70 : 30); [α]D
28
 +31 (c 1.00, CHCl3); IR (thin film) 3381 
(br), 2916, 2867, 1656, 1448, 1053 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 4.64 (t, 1H, J = 
3.3 Hz, C=CH), 3.76–3.61 (app t, 1H, J = 8.4 Hz, CHOH), 3.55 (s, 3H, OCH3), 2.91–
2.81 (m, 1H), 2.77–2.45 (m, 3H), 2.19–2.00 (m, 2H), 1.97–1.79 (m, 3H), 1.67-1.72 (m, 
1H), 1.65–1.57 (m, 3H), 1.48–1.02 (m, 8H), 0.76 (s, 3H, CCH3); 
13
C NMR (100 MHz, 
CDCl3) δ 152.6, 127.9, 125.0, 90.6, 81.9, 53.8, 49.9, 45.5, 43.3, 38.9, 37.0, 34.1, 30.6, 
30.5, 28.3, 26.7, 25.4, 23.0, 11.2; HRMS (CI) m/z: [M]
+
 calcd for C19H28O2 288.2089, 
found 288.2076. The analytical data are consistent with the data reported in the literature. 
 
(8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17-
dodecahydro-1H-cyclopenta[α]phenanthren-3(2H)-one (3) 
 
Experimental 
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Diene 2 (12.16 g, 42.16 mmol, 1.0 eq.) was heated in methanol (260 mL) at reflux. 
Aqueous HCl solution (3 M, 155 mL) was added and the reaction mixture was refluxed 
for 30 min turning from colourless to yellow. Water (300 mL) was added and the mixture 
was extracted with DCM (3 × 100 mL). The combined organic extracts were dried over 
MgSO4, concentrated in vacuo and the residue was purified by flash column 
chromatography (pentane : ethyl acetate, 50 : 50 → ethyl acetate) to give enone 3 (11.0 g, 
95% yield) as an orange foam. 
Rf 0.29 (pentane : ethyl acetate, 50 : 50); [α]D
28
 +52 (c 1.00, CHCl3); IR (thin film) 3405 
(br), 2924, 2864, 1655, 1618, 1055 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 5.83 (s, 1H, 
C=CH), 3.67 (app t, 1H, J = 8.4 Hz, CHOH), 2.51–2.36 (m, 2H), 2.34–2.19 (m, 3H), 
2.16–2.02 (m, 2H), 1.91–1.78 (m, 3H), 1.66–1.23 (m, 8H), 1.15–0.98 (m, 3H), 0.81 (s, 
3H, CCH3); 
13
C NMR (100 MHz, CDCl3) δ 199.9, 166.6, 124.6, 81.7, 49.7, 49.6, 43.0, 
42.6, 40.5, 36.5, 36.4, 35.5, 30.7, 30.4, 26.6, 26.1, 23.2, 11.0; HRMS (ES+) m/z: [M+H]
+
 
calcd for C18H27O2 275.2011, found 275.2026. The analytical data are consistent with the 
data reported in the literature. 
 
(8R,9S,10R,13S,14S,17S)-13-methyl-2,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-
1H-cyclopenta[α]phenanthrene-3,17-diyl diacetate (5) 
 
A solution of enone 3 (11.0 g, 40.1 mmol, 1 eq.) and 4 equiv of sodium iodide (24.0 g, 
160.4 mmol, 4.0 eq.) in acetic anhydride (300 mL) was treated with trimethylsilyl 
chloride (17,4 mL, 160.4 mmol, 4.0 eq.) at 0 °C under a nitrogen atmosphere for 2 h. The 
reaction mixture was dried under reduced pressure, then the residue was dissolved in 
ethyl acetate. The solution was washed with 2% sodium thiosulfate, with a saturated 
solution of NaHCO3 and dried over MgSO4. After filtration the residue was purified by 
flash column chromatography (pentane : ethyl acetate, 90 : 10) to give diacetate 5 (10.1 
g, 70% yield) as a white solid. 
Experimental 
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Rf 0.40 (pentane : ethyl acetate, 90 : 10); mp 148–150 °C; lit: mp 165–169 °C; [α]D
28
 -
139 (c 1.00, CHCl3); IR (thin film) 2916, 2880, 2818, 1756, 1729, 1205 cm
-1
; 
1
H NMR 
(400 MHz, CDCl3) δ 5.76 (s, 1H, C=CH), 5.47 (s, 1H, C=CH), 4.62 (app t, 1H, J = 8.4 
Hz, CHOAc), 2.52–2.39 (m, 1H), 2.23–2.08 (m, 4H), 2.13 (s, 3H, COCH3), 2.04 (s, 3H, 
COCH3), 1.95–1.83 (m, 2H), 1.79–1.59 (m, 4H), 1.52–1.18 (m, 7H), 1.14-1.06 (m, 2H), 
0,99-0,88 (m, 1H), 0.82 (s, 3H, CCH3); 
13
C NMR (100 MHz, CDCl3) δ 171.2, 169.2, 
148.7, 134.6, 123.7, 117.6, 82.8, 50.3, 43.6, 42.6, 40.6, 36.7, 36.6, 30.9, 28.0, 27.5, 27.2, 
26.3, 23.3, 21.2, 21.1, 11.9; HRMS (ES+) m/z: [M+H]
+
 calcd for C22H31O4 359.2222, 
found 359.2201. The analytical data are consistent with the data reported in the literature. 
 
(8R,9S,10R,13S,14S,17S)-13-methyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-
dodecahydro-1H-cyclopenta[α]phenanthren-17-yl acetate (6) 
 
Diacetate 5 (8.22 g, 22.93 mmol, 1 eq.) was suspended in a mixture of DMF (53 mL) and 
water (1.5 mL) at 0°C, then N-bromosuccinimide (4.33 gm, 24,31 mmol, 1.06 eq.) was 
added over 30 min. giving a cloudy solution. At the end of the addition the reaction 
mixture was stirred at 0°C for other 45 min., after which it becomes clear. To the 
resulting solution were added LiBr (0.868 g, 10.0 mmol, 1.99 eq.) and Li2CO3 (1.76 g, 
23.79 mmol, 4.74 eq.) and the mixture was heated at 110 °C for 1 h (it turns brown). 
After the suspension cooled down, the salts were removed by filtration and the solution 
was treated with a mixture of water (300 mL) and acetic acid (26 mL) turning from dark 
brown to bright orange. The solution was extracted three times with DCM (3 x 150 mL) 
and the combined organic extracts were washed with a saturated solution of NaHCO3 and 
then with brine. The organic solution was then dried over MgSO4, filtered and 
evaporated to dryness to give 6 (6.13 g, 85% yield) as an amber gummy solid. 
Rf 0.27 (pentane : ethyl acetate, 70 : 30); mp 88–90 °C; [α]D
27
 +36 (c 1.00, CHCl3); IR 
(thin film) 2971, 2945, 2860, 1729, 1663, 1248 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
6.20–6.14 (m, 2H, 2 × C=CH), 5.77 (d, 1H, J = 1.9 Hz, C=CH), 4.65 (app t, 1H, J = 8.4 
Hz, CHOAc), 2.55–2.50 (m, 1H), 2.37–2.12 (m, 5H), 2.04 (s, 3H, COCH3), 1.85–1.78 
Experimental 
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(m, 3H), 1.60–1.41 (m, 3H), 1.36–1.05 (m, 4H), 0.86 (s, 3H, CCH3); 
13
C NMR (100 
MHz, CDCl3) δ 200.0, 171.1, 158.7, 141.3, 128.9, 124.4, 82.1, 47.7, 45.9, 43.4, 41.1, 
40.8, 37.7, 36.4, 27.3, 26.9, 25.0, 22.9, 21.1, 11.8; HRMS (ES+) m/z: [M+H]
+
 calcd for 
C20H27O3 315.1960, found 315.1947. The analytical data are consistent with the data 
reported in the literature. 
 
(7R,8R,9S,10R,13S,14S,17S)-7-cyano-13-methyl-3-oxo-
2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[α]phenanthren-
17-yl acetate (7) 
 
Diethylaluminium cyanide (1.0 M in toluene, 11.8 mL, 3.71 eq.) was added to a solution 
of dienone 6 (1.0 g, 3.18 mmol, 1.0 eq.) in THF (51 mL) and the reaction mixture was 
stirred at room temperature for 1 h. Cold NaOH(aq) (0.5 M, 150 mL) was added and the 
mixture was extracted with DCM (3 × 100 mL). The combined organic extracts were 
washed with water (150 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (pentane : ethyl acetate, 50 : 50) 
to afford aliphatic nitrile 7 (0.824 g, 76% yield) as a white foam. 
Rf 0.34 (pentane : ethyl acetate, 50 : 50); [α]D
25
 +28 (c 1.00, CHCl3); IR (thin film) 2946, 
2864, 2240, 1728, 1669, 1241 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 5.93 (s, 1H, C=CH), 
4.65 (app t, 1H, J = 8.6, CHOAc), 3.01–2.97 (m, 1H, CHCN), 2.75 (dd, 1H, J = 14.8, 2.3 
Hz, CHaHbCHCN), 2.58–2.49 (m, 1H, CHaHbCHCN), 2.48-2.39 (m, 1H), 2.33–2.17 (m, 
3H), 2.14–2.04 (m, 1H), 2.02 (s, 3H, COCH3), 1.97–2.89 (m, 1H), 1.82–1.20 (m, 10H), 
0.84 (s, 3H, CCH3); 
13
C NMR (100 MHz, CDCl3) δ 198.6, 170.9, 158.5, 127.9, 118.9, 
81.9, 47.0, 44.7, 43.0, 42.1, 41.2, 37.4, 36.4, 35.9, 31.6, 27.2, 26.3, 25.8, 22.6, 21.0, 12.0; 
HRMS (ES+) m/z: [M+MeCN+H]
+
 calcd for C23H31N2O3 383.2335, found 383.2355. 
The analytical data are consistent with the data reported in the literature. 
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(7R,8R,9S,13S,14S,17S)-7-cyano-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[α]phenanthren-17-yl acetate (8) 
 
CuBr2 (3.91 g, 1.96 eq.) and LiBr (0.74 g, 1.0 eq.) were added to a suspension of 
aliphatic cyanide 7 (3.06 g, 8.96 mmol, 1.0 eq.) in acetonitrile (41 mL) and the reaction 
mixture was refluxed for 20 min. under argon atmosphere. The salts were removed by 
filtration and the mixture was stirred with saturated NaHCO3(aq) (200 mL) for 1 h. The 
solution was extracted with ethyl acetate (3 × 100 mL). The combined organic extracts 
were washed with brine (300 mL), dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by flash column chromatography (pentane : ethyl acetate, 60 : 
40 → 50 : 50) to afford phenolic compound 8 (2,71 g, 89% yield) as a white-pink solid. 
Rf 0.59 (pentane : ethyl acetate, 50 : 50); [α]D
29
 +17 (c 1.00, CHCl3); IR (thin film) 3374 
(br), 2940, 2244, 1735, 1245 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.18 (d, 1H, J = 8.4 
Hz, Ar-H), 6.69 (dd, 1H, J = 8.4, 2.7 Hz, Ar-H), 6.56 (d, 1H, J = 2.7 Hz, Ar-H), 4.98 (s, 
1H, Ar-OH), 4.74 (dd, 1H, J = 8.0, 9.1 Hz, CHOAc), 3.20–3.03 (m, 2H), 2.70–2.60 (m, 
1H), 2.45–2.22 (m, 2H), 2.06 (s, 3H, COCH3), 1.95–1.15 (m, 9H), 0.83 (s, 3H, CCH3); 
13
C NMR (100 MHz, CDCl3) δ 171.4, 154.1, 132.7, 130.0, 127.2, 120.2, 115.3, 114.2, 
82.2, 47.0, 43.2, 39.4, 39.2, 36.3, 32.6, 28.5, 27.4, 26.2, 22.6, 21.1, 12.0; The mass of the 
product could not be found by HRMS. The analytical data are consistent with the data 
reported in the literature. 
 
(7R,8R,9S,13S,14S,17S)-3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[α]phenanthrene-7-carbaldehyde (9) 
 
Experimental 
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A solution of DIBAL-H (1.0 M in toluene, 1.24 mL, 4.2 eq.) was added to a solution of 
cyanide 8 (100 mg, 0.295 mmol, 1.0 eq.) in toluene (2.9 mL) at 0°C and the reaction 
mixture was stirred vigorously at room temperature for 3 h. Methanol (2.1 mL) and 
HCl(aq) (2 M, 1.2 mL) were added slowly and the mixture was stirred at room 
temperature for 30 min. The suspension was partitioned between ethyl acetate (50 mL) 
and water (50 mL) and extracted with ethyl acetate (2 × 100 mL). The combined organic 
extracts were washed with brine (100 mL), dried over MgSO4 and concentrated in vacuo. 
The crude product was purified by flash column chromatography (pentane : ethyl acetate, 
50 : 50) to afford aldehyde 9 (72 mg, 81% yield) as a white solid. 
Rf 0.36 (pentane : ethyl acetate, 50 : 50); [α]D
29
 +20 (c 1.00, MeOH); IR (thin film) 3242 
(br), 2931, 1705, 1226, 1011 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 9.83 (d, 1H, J = 2.0 
Hz, CHO), 7.16 (d, 1H, J = 8.5 Hz, Ar-H), 6.65 (dd, 1H, J = 8.4, 2.7 Hz, Ar-H), 6.62 (d, 
1H, J = 2.6 Hz, Ar-H), 4.7 (br s, 1H, Ar-OH), 3.78 (app t, 1H, J = 8.3 Hz, CHOH), 3.17 
(d, 1H, J = 17.3 Hz, Ar-CHaHb), 3.00 (dd, 1H, J = 17.3, 6.2 Hz, Ar-CHaHb), 2.72 (m, 
1H), 2.45–2.33 (m, 2H), 2.23–2.15 (m, 1H), 1.96–1.84 (m, 3H), 1.68–1.43 (m, 4H), 
1.33–1.24 (m, 2H, CH), 0.90-0.83 (m, 1H), 0.80 (s, 3H, CCH3); 
13
C NMR (125 MHz, 
CDCl3) δ 204.7, 153.9, 135.3, 131.4, 127.2, 115.5, 113.7, 81.7, 46.9, 46.4, 43.8, 41.2, 
39.7, 36.6, 30.5, 30.2, 27.4, 23.0, 10.6; HRMS (ES+) m/z: [M+H]
+
 calcd for C19H25O3 
301.1798, found 301.1799. The analytical data are consistent with the data reported in 
the literature. 
 
(7R,8R,9S,13S,14S,17S)-7-formyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-
6H-cyclopenta[α]phenanthrene-3,17-diyl diacetate (10) 
 
Aldehyde 9 (1.0 g, 3.33 mmol, 1.0 eq.) was suspended in DCM (20 mL), then Et3N (2.3 
mL, 16.6 mmol, 5 eq.) was added to give a clear solution. A catalytic amount of DMAP 
(40.3 mg, 0.33 mmol, 0.1 eq.) was added the solution was cooled to 0 °C. Acetic 
anhydride (0.94 mL, 9.99 mmol, 3 eq.) was added dropwise to the cold solution and the 
Experimental 
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reaction mixture was stirred for 1.30 h. Saturated NaHCO3(aq) was added until pH 
remained basic. 100 mL of DCM were added, the organic phase collected, washed with a 
10% solution of citric acid in water and washed with saturated NaHCO3(aq) again. The 
combined organic extracts were dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (pentane : ethyl acetate, 70 : 30) 
to afford diacetate 10 (1.10 g, 86% yield) as a white foam. 
Rf 0.71 (pentane : ethyl acetate, 2 : 1); [α]D
27
 +28 (c 1.00, CHCl3); IR (thin film) 2931, 
1760, 1726, 1204, 1012 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 9.84 (s, 1H, CHO), 7.32–
7.27 (m, 1H, Ar-H), 6.92–6.85 (m, 2H, 2 × Ar-H), 4.73 (dd, 1H, J = 9.1, 7.6 Hz, 
CHOAc), 3.21 (d, 1H, J = 17.2 Hz, Ar-CHaHb), 3.03 (dd, 1H, J = 17.4, 6.4 Hz, Ar-
CHaHb), 2.79–2.70 (m, 1H), 2.58–2.44 (m, 1H), 2.44–2.31 (m, 1H), 2.31–2.24 (m, 1H), 
2.28 (s, 3H, COCH3), 2.06 (s, 3H, COCH3), 1.97–1.83 (m, 3H), 1.81–1.68 (m, 1H), 1.67–
1.33 (m, 4H), 0.84 (s, 3H, CCH3); 
13
C NMR (125 MHz, CDCl3) δ 204.2, 171.1, 169.7, 
148.8, 136.4, 135.3, 127.1, 121.8, 119.4, 82.3, 46.5, 46.1, 43.3, 40.3, 39.6, 36.6, 29.8, 
27.4, 26.9, 23.1, 21.1 (2C), 11.5; HRMS (CI) m/z: [M+NH4]
+
 calcd for C23H32NO5 
402.2280, found 402.2291. The analytical data are consistent with the data reported in 
the literature. 
 
 (7R,8R,9S,13S,14S,17S)-7-(hydroxymethyl)-13-methyl-7,8,9,11,12,13,14,15,16,17-
decahydro-6H-cyclopenta[α]phenanthrene-3,17-diyl diacetate (11) 
 
NaBH4 (0.36 g, 9.63 mmol, 1.9 eq.) was added to a solution of aldehyde 10 (1.95 g, 5.07 
mmol, 1.0 eq.) in EtOH (60 mL) at 0 °C and the reaction mixture was stirred for 30 min. 
The solution was poured into 250 mL of saturated ammonium chloride, washed with 
aqueous NaHCO3 solution (10%) and extracted with ethyl acetate (3 × 200 mL). The 
combined organic extracts were washed with brine (200 mL), dried over MgSO4 and 
concentrated in vacuo. The crude product was purified by flash column chromatography 
(pentane : ethyl acetate, 60 : 40) to afford alcohol 11 (1.57 g, 80% yield) as a white foam. 
Experimental 
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Rf 0.40 (pentane : ethyl acetate, 60 : 40); [α]D
27
 +32 (c 1.00, CHCl3); IR (thin film) 3447 
(br), 2935, 1760, 1730, 1206, 1024 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.27 (d, 1H, J = 
8.3 Hz, Ar-H), 6.85 (dd, 1H, J = 8.3, 2.0 Hz, Ar-H), 6.82 (d, 1H, J = 2.0 Hz, Ar-H), 4.69 
(dd, 1H, J = 9.0, 7.8 Hz, CHOAc), 3.75 (dd, 1H, J = 10.1, 3.9 Hz, CHaHbOH), 3.46 (app 
t, 1H, J = 10.1, CHaHbOH), 3.01 (dd, 1H, J = 17.2, 1.9 Hz, Ar-CHaHb), 2.93 (m, 1H, Ar-
CHaHb), 2.40–2.17 (m, 3H), 2.28 (s, 3H, COCH3), 2.14–2.01 (m, 1H), 2.06 (s, 3H, 
COCH3), 1.95–1.69 (m, 3H), 1.63–1.26 (m, 6H), 0.82 (s, 3H, CCH3); 
13
C NMR (125 
MHz, CDCl3) δ 171.2, 169.8, 148.6, 136.7, 136.5, 127.1, 122.4, 118.9, 82.5, 60.7, 46.6, 
43.2, 40.1, 38.9, 36.9, 35.9, 32.5, 27.5, 27.2, 22.8, 21.2, 21.1, 11.8; HRMS (ES+) m/z: 
[M+H]
+ 
calcd for C23H31O5 387.2171, found 387.2184. The analytical data are consistent 
with the data reported in the literature. 
 
 (7R,8R,9R,13S,14S,17S)-13-methyl-6,7,8,11,12,13,14,15,16,17-decahydro-9,7-
(epoxymethano)cyclopenta[α]phenanthrene-3,17-diyl diacetate (12) 
 
To a solution of alcohol 11 (1.57 g, 4.06 mmol, 1.0 eq.) in carbon disulfide (125 mL) was 
added iodine (1.03 g, 4.06 mmol 1.0 eq.) and lead tetraacetate (7.38 g, 16.65 mmol, 4.1 
eq.) and the reaction mixture was refluxed for 1 h. The solvent was evaporated in vacuo 
and the residue was dissolved in DCM (200 mL), washed with aqueous NaS2O3 (10% wt, 
3 × 100 mL), brine (100 mL), dried over MgSO4 and concentrated in vacuo. The crude 
product was purified by flash column chromatography (pentane : ethyl acetate, 70 : 30) 
to afford benzylic ether 12 (1.27 g, 81% yield) as a white foam. 
Rf 0.43 (pentane : ethyl acetate, 70 : 30); [α]D
30
 –31 (c 1.00, CHCl3); IR (thin film) 2936, 
1753, 1730, 1247, 1201 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 7.34 (d, 1H, J = 8.2 Hz, Ar-
H), 6.90–6.82 (m, 2H, 2 × Ar-H), 4.67 (dd, 1H, J = 9.0, 7.8 Hz, CHOAc), 4.09 (ddd, 1H, 
J = 8.4, 5.9, 2.3 Hz, CHaHbO), 3.61 (d, 1H, J = 8.6 Hz, CHaHbO), 3.13 (app d, 1H, J = 
16.9 Hz, Ar-CHaHb), 2.86 (dd, 1H, J = 17.1, 2.1 Hz, Ar-CHaHb), 2.58–2.37 (m, 2H), 2.28 
(s, 3H, COCH3), 2.35–2.21 (m, 1H), 2.12-2.00 (m, 1H), 2.05 (s, 3H, COCH3), 2.00–1.92 
(m, 1H), 1.81–1.70 (m, 2H), 1.65–1.51 (m, 2H), 1.47–1.37 (m, 2H), 0.79 (s, 3H, CCH3); 
Experimental 
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13
C NMR (125 MHz, CDCl3) δ 171.1, 169.6, 149.8, 140.3, 136.2, 124.9, 122.2, 119.0, 
82.2, 79.6, 71.1, 46.7, 42.2, 42.0, 38.3, 37.5, 32.6, 27.6, 26.2, 23.5, 21.1 (2C), 10.6; 
HRMS (ES+) m/z: [M+H]
+
 calcd for C23H29O5 385.2015, found 385.2008. The analytical 
data are consistent with the data reported in previous work in Barrett research group
24
. 
 
 (7R,8R,13S,14S,17S)-7-(hydroxymethyl)-13-methyl-7,8,12,13,14,15,16,17-
octahydro-6H-cyclopenta[α]phenanthrene-3,17-diyl diacetate (13) 
 
To a stirring solution of benzyl ether 12 (500 mg, 1.3 mmol, 1 eq.) in DCM (30 mL), 
FeCl3 (253 mg, 1.56 mmol, 1.2 eq.) and allyltrimethylsilane (1.49 g, 13.0 mmol, 10 eq.) 
were added and the mixture was stirred at room temperature for 30 min. The reaction was 
quenched with saturated NaHCO3 and extracted with DCM (2 x 25 mL). The combined 
organic phases were washed with brine, dried over MgSO4 and concentrated in vacuo to 
give alcohol 13 (378 mg, 76% yield) as a white solid. 
Rf 0.23 (pentane : ethyl acetate, 20 : 10); 
1
H NMR (400 MHz, CDCl3) δ 7.61 (d, 1H, J = 
8.6 Hz, Ar-H), 6.88–6.81 (m, 2H, 2 × Ar-H), 6.35-6.29 (m, 1H, C=CH), 4.77 (app t, 1H, 
J = 8.6 Hz, CHOAc), 3.66 (dd, 1H, J = 10.7, 4.6 Hz, CHaHbOH), 3.61 (app t, 1H, J = 9.9 
Hz, CHaHbOH), 3.06 (dd, 1H, J = 16.8, 1.9 Hz, Ar-CHaHb), 2.96 (dd, 1H, J = 16.7, 4.8 
Hz, Ar-CHaHb), 2.47–2.39 (m, 1H), 2.28 (s, 3H, COCH3), 2.26–2.17 (m, 3H), 2.07 (s, 
3H, COCH3), 1.96–1.84 (m, 1H), 1.76–1.56 (m, 3H), 1.52–1.40 (m, 1H), 1.35 (br s, 1H), 
0.80 (s, 3H, CCH3); 
13
C NMR (125 MHz, CDCl3) δ 171.3, 169.8, 149.6, 135.2, 131.8, 
131.7, 124.5, 122.8, 121.0, 119.51, 82.7, 61.1, 42.9, 41.6, 41.1, 39.3, 36.1, 33.0, 29.8, 
27.7, 23.9, 21.3, 11.8; HRMS (ES+) m/z: [M+H]
+
 calcd for C23H29O5 385.2015, found 
385.2025. 
 
(7R,8R,13S,14S,17S)-7-((((iodomethyl)diisopropylsilyl)oxy)methyl)-13-methyl-
7,8,12,13,14,15,16,17-octahydro-6H-cyclopenta[α]phenanthrene-3,17-diyl diacetate 
(14) 
Experimental 
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To a stirred mixture of DMAP (10.8 mg, 0.088 mmol, 0.1 eq.), 
chloro(iodomethyl)diisopropylsilane (257 mg, 0.884 mmol, 1 eq.), Et3N (0.15 mL, 0.884 
mmol, 1 eq.) and DCM (2 mL), alcohol 13 (340 mg, 0.886 mmol, 1 eq.) in 0.7 mL of 
DCM was added at 0°C under argon atmosphere. The mixture was stirred until 
completion of the reaction (1 h 30 min) as judged by TLC. After completion the mixture 
was quenched with saturated ammonium chloride solution and extracted with DCM (3 x 
25 mL). The combined organic layer was dried with MgSO4, filtered and concentrated in 
vacuo. The residue was purified by flash chromatography in DCM to give silylated 
steroid 14 (89% yield) a viscous colourless oil. 
Rf 0.60 (pentane : ethyl acetate, 90 : 10); [α]D
27
 +5 (c 1.00, CHCl3); IR (thin film) 2943, 
2866, 1764, 1734, 1491, 1370, 1242, 1202, 1098 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δ 
7.60 (d, 1H, J = 8.7 Hz, Ar-H), 6.85 (dd, 1H, J = 8.7, 2.5 Hz, Ar-H), 6.81 (d, 1H, J = 2.5 
Hz, Ar-H), 6.32 (m, 1H, C=CH), 4.77 (app t, 1H, J = 8.7 Hz, CHOAc), 3.75 (dd, 1H, J = 
10.0, 5.4 Hz, CHaHbOSi), 3.37 (dd, 1H, J = 10.0, 8.7 Hz, CHaHbOSi), 3.06 (dd, 1H, J = 
16.8, 1.8 Hz, Ar-CHaHb), 2.93 (dd, 1H, J = 16.6, 4.9 Hz, Ar-CHaHb), 2.46–2.38 (m, 1H), 
2.32-2.15 (m, 3H), 2.27 (s, 3H, COCH3), 2.07 (s, 3H, COCH3), 1.96 (s, 2H, CH2I), 1.96–
1.88 (m, 1H), 1.83–1.73 (m, 1H), 1.68-1.56 (m, 1H), 1.52-1.40 (m, 1H), 1.20-1.10 (m, 
2H), 1.10-1.04 (m, 4H), 1.04-0.94 (m, 12H, 2 x CH(CH3)2), 0.79 (s, 3H, CCH3); 
13
C 
NMR (100 MHz, CDCl3) δ 171.2 (Cq), 169.6 (Cq), 149.6 (Cq), 135.5 (Cq), 131.9 (Cq), 
131.7 (Cq), 124.4, 122.7, 120.9, 119.3, 82.7, 62.4 (CH2), 43.0, 41.6 (Cq), 41.2, 39.4 
(CH2), 36.4, 33.3 (CH2), 27.7 (CH2), 24.0, 21.3 (CH2), 17.8, 17.6, 12.4, 12.3, 11.7, -20.8 
(CH2I); HRMS (ES+) m/z: [M+H]
+
 calcd for C30H44O5SiI 639.2003, found 639.2007. 
 
(chloromethyl)diisopropylsilane (16) 
 
Experimental 
36 
To a solution of dichlorodiisopropylsilane (5 g, 33.17 mmol, 1 eq.) and  
chloroiodomethane (8.78 g, 49.76 mmol, 1.5 equiv) in THF (41 mL) was added a 
solution of MeLi-LiBr complex (1.5 M in ether, 33.2 mL, 60 mmol, 1.5 eq.) dropwise at 
-78 °C. The reaction mixture was stirred at -78 °C for 1 h and then allowed to warm to 
room temperature before quenching with saturated ammonium chloride solution. The 
aqueous layer was extracted with pentane. The combined organic layer was dried over 
MgSO4 and concentrated in vacuo. The crude product, (chloromethyl)diisopropylsilane, 
was used for the next step without further purification. 
1
H NMR (400 MHz, CDCl3) δ 3.63 (app quint, 1H, J = 2.4 Hz, SiH), 2.95 (d, 2H, J = 2.3 
Hz, CH2Cl), 1.23-1.13 (m, 2H, 2 x CH(CH3)2), 1.12-1.05 (m, 12H, 2 x CH(CH3)2). 
 
(iodomethyl)diisopropylsilane (17) 
 
To a solution of NaI (15 g, 99.5 mmol, 3 eq.) in ACS standard acetone (30 mL) was 
added crude (chloromethyl)diisopropylsilane in acetone (5 mL). The reaction mixture 
was refluxed at 85 °C for 1h. The reaction was allowed to cool to room temperature 
before quenching with saturated solution of Na2S2O3.The aqueous layer was extracted 
with pentane. The combined organic layer was dried over MgSO4 and concentrated in 
vacuo. The crude product, iodomethyl)diisopropylsilane, a pale yellow oil, 7.04 g, (83 % 
yield over 2 steps) was used for the next step without further purification. 
1
H NMR (400 MHz, CDCl3) δ 3.82 (app quint, 1H, J = 2.7 Hz, SiH), 2.05 (d, 2H, J = 2.9 
Hz, CH2I), 1.22-1.12 (m, 2H, 2 x CH(CH3)2), 1.11-1.06 (m, 12H, 2 x CH(CH3)2). 
 
chloro(iodomethyl)diisopropylsilane (18) 
 
To a solution of TCCA (1.14 g, 4.92 mmol, 0.36 eq.) in dry DCM (31 mL) under argon 
was added crude (chloromethyl)diisopropylsilane (3.5 g, 13.7 mmol, 1 eq.) in DCM (4 
Experimental 
37 
mL) dropwise at 0 °C for 1 h. The mixture was allowed to warm to room temperature and 
was then filtered through celite and concentrated. The residue was then dissolved in 
pentane and re-filtered through celite and then concentrated to give crude 
chloro(iodomethyl)diisopropylsilane (3.81 g, yield 96%) as a pink/purple oil. The crude 
product, >95% purity by NMR, was used for the next step without further purification. 
1
H NMR (400 MHz, CDCl3) δ 2.22 (s, 2H, CH2I), 1.43 (sep, 2H, J = 7.5 Hz, 2 x 
CH(CH3)2), 1.16-1.10 (m, 12H, 2 x CH(CH3)2); 
13
C NMR (100 MHz, CDCl3) δ 17.4, 
17.1, 13.6, -20.7. The analytical data are consistent with the data reported in the 
literature. 
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